Targeting antibodies for the treatment of aggressive cancer
Targinta develops targeting and toxin-armed antibodies for aggressive cancer. The company was founded based on the discovery of a unique and patent-protected target molecule, integrin α10β1, and the aim is to improve the treatment of cancer, with a focus invasive, hard-to treat cancer forms isuch as triple-negative breast cancer and the brain cancer glioblastoma.
Targinta AB, a subsidiary of Xintela AB (publ)
The research that led to Targinta’s oncology initiative began at Xintela AB. Targinta is a wholly owned subsidiary of Xintela, which is listed on First North Stockholm.